课题基金 / 基金详情

LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA

LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
LCCC 0424：I 期厄洛替尼每 72 小时给予胶质母细胞瘤患者一次
批准号：
7625621
负责人：
CELESTE M LINDLEY
金额：
$0.41万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-12-01 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7625621
关键词：
Brain NeoplasmsComputer Retrieval of Information on Scientific Projects DatabaseDoseErlotinibFundingGlioblastomaGrantHourInstitutionPatientsPhaseResearchResearch PersonnelResourcesSourceTreatment ProtocolsUnited States National Institutes of Healthresearch study

项目摘要

项目成果

CELESTE M LINDLEY的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a research study to investigate a new dosing regimen of erlotinib in patients with glioblastoma multiforme, a type of brain tumor, who have failed first line therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CYP2B6 GENOTYPE-PHENOTYPE AND THE INFLUENCE OF SEX AND ETHNICITY
EVALUATING THE EFFECT OF APREPITANT ON CYCLOPHOSPHAMIDE PHARMACOKINETICS
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
VALIDATING BUPROPION AS AN IN VIVO PROBE FOR HUMAN CYTOCHROME P450 2B6